Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified

Omnicell

(

OMCL

) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Omnicell as such a stock due to the following factors:

  • OMCL has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $8.0 million.
  • OMCL has traded 1,540 shares today.
  • OMCL is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in OMCL with the Ticky from Trade-Ideas. See the FREE profile for OMCL NOW at Trade-Ideas

More details on OMCL:

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates in two segments, Automation and Analytics, and Medication Adherence. OMCL has a PE ratio of 46. Currently there are 4 analysts that rate Omnicell a buy, no analysts rate it a sell, and 2 rate it a hold.

Scroll to Continue

TheStreet Recommends

The average volume for Omnicell has been 182,200 shares per day over the past 30 days. Omnicell has a market cap of $1.4 billion and is part of the technology sector and computer software & services industry. The stock has a beta of 0.65 and a short float of 2.2% with 3.42 days to cover. Shares are up 18.6% year-to-date as of the close of trading on Friday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Omnicell as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

Highlights from the ratings report include:

  • Compared to its closing price of one year ago, OMCL's share price has jumped by 35.16%, exceeding the performance of the broader market during that same time frame. Regarding the stock's future course, although almost any stock can fall in a broad market decline, OMCL should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.
  • OMCL's revenue growth trails the industry average of 42.1%. Since the same quarter one year prior, revenues rose by 14.2%. This growth in revenue does not appear to have trickled down to the company's bottom line, displaying stagnant earnings per share.
  • OMCL has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. To add to this, OMCL has a quick ratio of 2.10, which demonstrates the ability of the company to cover short-term liquidity needs.
  • Net operating cash flow has significantly increased by 912.89% to $11.31 million when compared to the same quarter last year. In addition, OMNICELL INC has also vastly surpassed the industry average cash flow growth rate of 49.57%.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.